KRAS G12C inhibitor
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for KRAS G12C inhibitor, covering 2026-04-21 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer [Phase 2]